MX2022003217A - Conjugados terapeuticos. - Google Patents

Conjugados terapeuticos.

Info

Publication number
MX2022003217A
MX2022003217A MX2022003217A MX2022003217A MX2022003217A MX 2022003217 A MX2022003217 A MX 2022003217A MX 2022003217 A MX2022003217 A MX 2022003217A MX 2022003217 A MX2022003217 A MX 2022003217A MX 2022003217 A MX2022003217 A MX 2022003217A
Authority
MX
Mexico
Prior art keywords
therapeutic conjugates
conjugates
therapeutic
administering
compositions
Prior art date
Application number
MX2022003217A
Other languages
English (en)
Inventor
Neil Sonin Dhawan
James Abellera Blair
Robert B Perni
Original Assignee
Totus Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Totus Medicines Inc filed Critical Totus Medicines Inc
Publication of MX2022003217A publication Critical patent/MX2022003217A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Conjugados terapéuticos que se unen covalentemente a una diana biológica. También se describen métodos para administrar las composiciones a un sujeto que lo necesite.
MX2022003217A 2019-09-19 2020-09-18 Conjugados terapeuticos. MX2022003217A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902554P 2019-09-19 2019-09-19
US202063078055P 2020-09-14 2020-09-14
PCT/US2020/051491 WO2021055747A1 (en) 2019-09-19 2020-09-18 Therapeutic conjugates

Publications (1)

Publication Number Publication Date
MX2022003217A true MX2022003217A (es) 2022-06-29

Family

ID=74883745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003217A MX2022003217A (es) 2019-09-19 2020-09-18 Conjugados terapeuticos.

Country Status (16)

Country Link
US (3) US20220387603A1 (es)
EP (1) EP4031143A4 (es)
JP (1) JP2022548135A (es)
KR (1) KR20220079866A (es)
CN (1) CN114599366A (es)
AU (1) AU2020349543A1 (es)
BR (1) BR112022005026A2 (es)
CA (1) CA3154079A1 (es)
CL (1) CL2022000665A1 (es)
CO (1) CO2022003703A2 (es)
IL (1) IL291486A (es)
MX (1) MX2022003217A (es)
PE (1) PE20230091A1 (es)
TW (1) TW202126307A (es)
WO (1) WO2021055747A1 (es)
ZA (1) ZA202203201B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003217A (es) 2019-09-19 2022-06-29 Totus Medicines Inc Conjugados terapeuticos.
EP4308121A1 (en) * 2021-03-18 2024-01-24 Totus Medicines Inc. Therapeutic conjugates
WO2023179771A1 (en) 2022-03-24 2023-09-28 Totus Medicines Inc. Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof
WO2023183936A2 (en) * 2022-03-24 2023-09-28 Totus Medicines Inc. Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
SG179085A1 (en) * 2009-09-09 2012-04-27 Avila Therapeutics Inc Pi3 kinase inhibitors and uses thereof
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
US20120231963A1 (en) 2011-03-10 2012-09-13 Raybiotech, Inc, Biotin-label-based antibody array for high-content profiling of protein expression
HUE048834T2 (hu) * 2011-05-17 2020-08-28 Univ California Kináz inhibitorok
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) * 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN102675323B (zh) 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
EP3157920B1 (en) 2014-06-17 2019-08-07 Chiesi Farmaceutici S.p.A. Indolizine derivatives as phosphoinositide 3-kinases inhibitors
EP3191126B1 (en) * 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN109111447A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
CA3071534A1 (en) 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
CN109081905A (zh) 2018-08-03 2018-12-25 浩力森涂料（上海）有限公司 水性环氧固化剂及其制备方法
WO2020052772A1 (en) 2018-09-13 2020-03-19 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Modulation of trf1 for brain cancer treatment
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
MX2022003217A (es) 2019-09-19 2022-06-29 Totus Medicines Inc Conjugados terapeuticos.
WO2021243421A1 (en) 2020-06-05 2021-12-09 Monash University Dual kinase-bromodomain inhibitors

Also Published As

Publication number Publication date
CO2022003703A2 (es) 2022-07-08
IL291486A (en) 2022-05-01
AU2020349543A1 (en) 2022-03-24
US20220387603A1 (en) 2022-12-08
JP2022548135A (ja) 2022-11-16
ZA202203201B (en) 2023-11-29
TW202126307A (zh) 2021-07-16
EP4031143A4 (en) 2023-11-01
EP4031143A1 (en) 2022-07-27
BR112022005026A2 (pt) 2022-06-21
US11484597B2 (en) 2022-11-01
CN114599366A (zh) 2022-06-07
WO2021055747A1 (en) 2021-03-25
PE20230091A1 (es) 2023-01-16
KR20220079866A (ko) 2022-06-14
CL2022000665A1 (es) 2022-10-28
CA3154079A1 (en) 2021-03-25
US20220211855A1 (en) 2022-07-07
US20230096658A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
ZA202203201B (en) Therapeutic conjugates
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
EP4219563A3 (en) Methods of treating cancer with anti-pd-1 antibodies
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
MX2020001513A (es) Agentes de union a clec9a y su uso.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
UA110370C2 (en) Conjugates of amatoxin with improved linkages
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
MX2018009085A (es) Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
MX2020004691A (es) Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
CR20220057A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
MX2020003089A (es) Analogos de tailanstatina.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2021003295A (es) Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.